Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Profiling Responders to Standard Treatments in Status Migrainosus
NCT03066544Phase 2Unknown
- Sponsor
- Hartford HealthCare
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of bupivacaine hydrochloride 0.75% injection, naratriptan, dexamethasone, ketorolac in status migrainosus (SM), sponsored by Hartford HealthCare. Status: unknown.
02
Drugs
bupivacaine hydrochloride 0.75% injectionnaratriptandexamethasoneketorolac
03
Conditions
status migrainosus (SM)
Beyond the preview
Go deeper on NCT03066544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066544.